Alpine Immune Sciences Reports Preliminary, As Of September 30, 2023, Approximately $227.2M In Cash, Cash Equivalents, Restricted Cash And Investments
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences has reported preliminary financial results as of September 30, 2023, indicating approximately $227.2M in cash, cash equivalents, restricted cash, and investments.
November 06, 2023 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences has reported a strong financial position with $227.2M in cash and investments as of Q3 2023.
The news directly pertains to Alpine Immune Sciences and its financial position. The reported $227.2M in cash and investments indicates a strong financial position, which could potentially attract investors and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100